Polycystic kidney disease clinical trials

Explore recruiting polycystic kidney disease clinical trials.

Recruiting polycystic kidney disease studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Polycystic kidney disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects with Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Spain, Portugal, Germany, Netherlands, France, Italy +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Treatment of vascular stiffness in patients with autosomal dominant polycystic kidney disease

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

Study of Empagliflozin in Patients with Autosomal Dominant Polycystic Kidney Disease

Germany

Therapeutic use (Phase IV) EU CTIS Study details

STOP-PKD: SGLT2-inhibition to improve Prognosis in Polycystic Kidney Disease

Netherlands, Austria, Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Safety of rotigotine in patients with autosomal dominant polycystic kidney disease - ETERNAL-PKD

France

Therapeutic exploratory (Phase II) EU CTIS Study details

HYDROchlorothiazide to PROTECT polycystic kidney disease patients and improve their quality of life (HYDRO-PROTECT)

Spain, France, Netherlands, Belgium, Germany, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

Polycystic kidney disease trials by city

Polycystic kidney disease clinical trials

Recruiting polycystic kidney disease studies right now

Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease

A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease

Metabolic Impacts of Ren-Nu: A Dietary Program for Polycystic Kidney Disease

Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003

Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Shared Decision Making for Choosing Autosomal DOminant Polycystic Kidney Disease Treatment

Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney Disease

Implementation of Metformin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Disease (IMPEDE-PKD)

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Effects of Exogenous Ketosis on Proteinuria and Renal Function